Cepheid Revenue and Competitors
Estimated Revenue & Valuation
- Cepheid's estimated annual revenue is currently $750M per year.
- Cepheid's estimated revenue per employee is $127,378
- Cepheid's total funding is $117.9M.
Employee Data
- Cepheid has 5888 Employees.
- Cepheid grew their employee count by -2% last year.
Cepheid's People
Name | Title | Email/Phone |
---|---|---|
1 | Sr. Product Owner - Digital Solutions | Reveal Email/Phone |
2 | Chairman & CEO | Reveal Email/Phone |
3 | Chief IP Counsel | Reveal Email/Phone |
4 | Chief Product Security Officer/Director Software | Reveal Email/Phone |
5 | Executive Assistant to VP, Strategic Development | Reveal Email/Phone |
6 | VP, Manufacturing Finance | Reveal Email/Phone |
7 | VP Quality (OUS) | Reveal Email/Phone |
8 | VP, Software Engineering, R&D | Reveal Email/Phone |
9 | VP, Global Training & Development | Reveal Email/Phone |
10 | VP, Strategy and Business Development | Reveal Email/Phone |
Cepheid Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $3.5M | 38 | 27% | N/A | N/A |
#2 | $158.4M | 791 | 14% | $2.3M | N/A |
#3 | $42310M | 169995 | 5% | N/A | $226.6B |
#4 | $84.2M | 457 | 0% | $2.6M | N/A |
#5 | $38M | 245 | 47% | N/A | N/A |
What Is Cepheid?
Cepheid develops, manufactures, and markets fully-integrated systems that perform genetic analysis, including DNA and RNA analysis, for the clinical genetic assessment, biothreat, and life sciences markets. Our systems enable rapid, sophisticated genetic testing of organisms by automating otherwise complex manual laboratory procedures. Genetic testing involves a number of complicated steps, including sample preparation, amplification and detection. Based on state-of-the-art microfluidic and microelectronic technologies, our easy-to-use systems integrate these steps and analyze complex biological samples in our proprietary test cartridges. We are focusing our efforts on those applications where rapid genetic testing is particularly important, such as the infectious disease, cancer and biothreat testing markets. Our SmartCycler® and GeneXpert® systems can perform a broad range of genetic tests that include identifying infectious organisms and evaluating at-risk populations for the early detection of disease. Physicians can also determine the stage of a disease, such as cancer, and assess what therapy might be most effective. We have also adapted our systems to enable the rapid detection and identification of organisms that may serve as biothreat agents.
keywords:Biotechnology$117.9M
Total Funding
5888
Number of Employees
$750M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cepheid News
Cepheid Inc, Becton Dickinson, Hain LifeSciences, Abbott Laboratories, Alere, Roche AG, Hologic Corporation, bioMerieux, Sanofi, QIAGEN, Akonni Biosystems,...
LISBON, Portugal Cepheid is developing an assay for its flagship GeneXpert platform to differentiate bacterial from viral infections in...
BioMerieux, Cepheid, Danaher, Bruker, Becton Dickinson, Hologic, Roche Diagnostics, Alere. This comprehensive Clinical Microbiology Market...
SUNNYVALE, Calif., July 29, 2021 /PRNewswire/ -- Today Cepheid announced that it has received CE-IVD clearance for Xpert® HIV-1 Viral Load XC and Xpert® HIV-1 Qual XC, next-generation extended-coverage (XC) tests for HIV testing. Xpert® HIV-1 Viral Load XC adds a second target for HIV-1 detecti ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3130M | 8082 | N/A | N/A |
#2 | $1290M | 8201 | 8% | $481M |
#3 | $5490M | 9425 | 100% | N/A |
#4 | $1970.9M | 9709 | 2% | N/A |
#5 | $3560M | 9803 | 2% | $19.2M |